
Biocon sees mid-teens revenue growth on biosimilars, generics push
Biocon Ltd expects its overall revenue to grow in mid-teens this financial year, and the company is betting on a robust launch pipeline in its generics as well as biosimilars businesses to drive sales in the coming years, its chief executive and managing director Siddharth Mittal said on Tuesday. The Bengaluru-based company expects mid-to-high teens…